Diabetic retinopathy and coronary implantation of sirolimus-eluting stents

Journal of Interventional Cardiology

Volumn 20, Issue 2, 2007, Pages 122-131

  Ohno, Takayuki ^a   Takamoto, Shinichi ^a   Ando, Jiro ^a   Morita, Toshihiro ^a   Fujita, Hideo ^a   Hirata, Yasunobu ^a   Shigeeda, Takashi ^a   Hirose, Akira ^a   Nagai, Ryozo ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYPHER; RAPAMYCIN; UNCLASSIFIED DRUG;

ADJUSTMENT; ADULT; AGED; ARTICLE; CONFOUNDING VARIABLE; CONGENITAL BLOOD VESSEL MALFORMATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY BLOOD VESSEL; CORONARY RISK; CORONARY STENT; DEATH; DIABETES MELLITUS; DIABETIC RETINOPATHY; FEMALE; FOLLOW UP; HAZARD RATIO; HEART INFARCTION; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETINA; REVASCULARIZATION; TREATMENT OUTCOME;

AGED; CASE-CONTROL STUDIES; CORONARY ARTERIOSCLEROSIS; DIABETIC RETINOPATHY; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RISK; SIROLIMUS; STENTS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 33947413873     PISSN: 08964327     EISSN: 15408183     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2007.00252.x     Document Type: Article

References (25)

1. Kahn HA, Hiller R. Blindness caused by diabetic retinopathy. Am J Ophthalmol 1974;78:58-67.
2. Bailey CC, Sparrow LM. Co-morbidity in patients with sight-threatening diabetic retinopathy. Eye 2001;15:719-722.
3. Sullivan P, Caldwell G, Alexander N, et al. Long-term outcome after photocoagulation for proliferative diabetic retinopathy. Diabet Med 1990;7:788-794.
4. Uchio E, Inamura M, Ohno S, et al. Survival rate after vitreous surgery in patients with diabetic retinopathy. Ophthalmologica 1993;206:83-88.
5. Hanis CL, Chu HH, Lawson K, et al. Mortality of Mexican Americans with NIDDM. Diabetes Care 1993;16:82-89.
6. Gollamudi SR, Smidydy WE, Schachat AP, et al. Long-term survival rate after vitreous surgery for complications of diabetic retinopathy. Ophthalmology 1991;98:18-22.
7. Klein R, Klein BE, Moss SE, et al. Association of ocular disease and mortality in a diabetic population. Arch Ophthalmol 1999;117:1487-1495.
8. Klein BE, Klein R, McBride PE, et al. Cardiovascular disease, mortality, and retinal microvascular characteristics in type 1 diabetes: Wisconsin epidemiologic study of diabetic retinopathy. Arch Intern Med 2004;164:1917-1924.
9. Henricsson M, Nilsson A, Heiji A, et al. Mortality in diabetic patients participating in an ophthalmological control and screening programme. Diabet Med 1997;14:576-583.
10. Mittinen H, Haffner SM, Lehto S, et al. Retinopathy predicts coronary heart disease events in NIDDM patients. Diabetes Care 1996;19(12):1445-1448.
11. Toffvit O, Lövestam-Adrian M, Agardh E, et al. Nephropathy, but not retinopathy, is associated with the development of heart disease in type 1 diabetes: A 12-year observation study of 462 patients. Diabet Med 2005;22:723-729.
12. Ono T, Kobayashi J, Sasako Y, et al. The impact of diabetic retinopathy on long-term outcome following coronary artery bypass graft surgery. J Am Coll Cardiol 2002;40:428-436.
13. Ono T, Ohashi T, Asakura T, et al. The impact of diabetic retinopathy on cardiac outcome following coronary-artery-bypass graft surgery: A prospective observational study. Ann Thorac Surg 2006;81:608-612.
14. Briguori C, Condorelli G, Airoldi F, et al. Impact of microvascular complications on outcome after coronary stent implantations in patients with diabetes. J Am Coll Cardiol 2005;45:464-466.
15. Babapulle MN, Joseph L, Belisle P, et al. A hierarchical Bayesian meta-analysis of randomized clinical trials of drug-eluting stents. Lancet 2004;364:583-591.
16. Dibra A, Kastrati A, Mehilli J, et al. ISAR-DIABETES Study Investigators. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 2005;353:663-670.
17. Holmes DR Jr, Leon MB, Moses JW, et al. Analysis of 1-year clinical outcome in the SIRIUS trial. A randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 2004;109:634-640.
18. Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy: ETDRS report number 12. Ophthalmology 1991;98:Suppl:823-833.
19. Moses JW, Leon MB, Popma JJ, et al. SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-1323.
20. Windecker S, Remondino A, Eberli FR, et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med 2005;353:653-662.
21. Kastrati A, Dibra A, Mehilli J, et al. Predictive factors of restenosis after coronary implantation of sirolimusor paclitaxel-eluting stents. Circulation 2006;113:2293-2300.
22. Shiojima I, Walsh K, et al. The role of vascular endothelial growth factor in restenosis: The controversy continues. Circulation 2004;110:2283-2286.
23. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor. Nat Med 2002;8:128-135.
24. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-1487.
25. Lip PL, Belgore F, Blann AD, et al. Plasma VEGF and soluble VEGF receptor FLT-1 in proliferative retinopathy: Relationship to endothelial dysfunction and laser treatment. Invest Ophthalmol Vis Sci 2000;41:2115-2119.